Merck, Roche in cancer diagnostics deal

Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop diagnostic assays for Merck's cancer candidates. Roche will provide array and immunohistochemical technologies for use in Merck's clinical cancer programs. Merck also will expand its use of Roche's AmpliChip p53 test to stratify and identify patients for enrollment in planned or ongoing trials. Last year, Merck received access to the microarray-based test for use in clinical trials to help identify patients most likely to respond to cancer treatments. Details were not disclosed. ...